Clinical trial · Interventional
Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer
[F18]EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Carcinoma of the Cervix
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The PI is no longer with our institution
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as fluorine F 18 EF5 PET/CT imaging, may help find oxygen in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This trial is studying fluorine F 18 EF5 PET/CT imaging to see how well it works in finding hypoxia in tumor cells of patients with locally advanced or recurrent/metastatic cervical cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fludeoxyglucose F 18 | Radiation | — | UNRESOLVED |
| fluorine F 18 EF5 | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- All subjects
- interventionNames
- Radiation: fludeoxyglucose F 18
- Radiation: fluorine F 18 EF5
Primary outcomes (1)
- measure
- Relationship Between Fluorine F 18 EF5 Uptake and Disease-free Survival and Overall Survival
- timeFrame
- 7 years
- description
- The study was terminated and no data are available to be reported
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of carcinoma of the cervix meeting 1 of the following criteria: * Pathologically confirmed, newly diagnosed stage IB-IVA (locally advanced) disease * Imaging evidence of recurrent or metastatic disease * Measurable disease, defined as ≥ 1 cm on anatomic imaging PATIENT CHARACTERISTICS: * Karnofsky performance status 70-100% * WBC \> 2,000/mm³ * Platelet count \> 90,000/mm³ * Total bilirubin \< 2.0 mg/dL * Creatinine \< 2.0 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No history of allergic reactions attributed to Flagyl (metronidazole) * No other condition or personal circumstance that, in the judgment of the Investigator, may interfere with the collection of complete, good-quality data PRIOR CONCURRENT THERAPY: * Not specified
References
Publications (0)
Data not yet available